Movement Disorders

Filter Your Results

 

News

 

Effect of Pimavanserin for Parkinson’s Disease Psychosis Found Larger in Patients with Impaired Cognition

Friday, November 02, 2018—A post hoc analysis of data from the 6‐week phase 3 trial (NCT01174004) of pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA) in patients with Parkinson’s …

Positive Top-Line Results Announced from Phase 2 Study of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder

Tuesday, October 30, 2018—Pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA), already approved for treatment of patients with Parkinson’s disease (PD) psychosis is also being studied …

Positive Two-Year Outcomes for Treatment of Essential Tremor With Focused Ultrasound

Tuesday, October 09, 2018—Patients with medically refractory essential tremor treated with magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy had a mean 43.4% reduction in their scores o…

Shortage of Sinemet Attribute to Manufacturing and Forecasting Issues

Thursday, October 04, 2018—The carbidopa-levodopa distributed under the brand names Sinemet and Sinemet Plus by Merck &Co. (Kenilworth, NJ) is out of stock and expected to be on back order through t…

Hometown Highlights: Introducing Hometown Highlights

Stephen M. Gollomp, MD

October 2018—In this new column, we feature content from presenters at the 2018-2019 Philadelphia Neurological Society meetings.

Movement Disorders Moment: Shining a Light on the Off Periods of Parkinson’s Disease

Jeffrey Lahrmann, MD; and Jill M. Giordano Farmer, DO

October 2018—New formulations for rescue from the off period are coming.

Smart Phone Tests May Distinguish Parkinson’s from Idiopathic REM Sleep Behavior Disorder

Tuesday, September 25, 2018—In a paper published in Neurology, researchers report that consumer-grade smartphones can be used to accurately identify patients with Parkinson’s disease (PD) versus th…

FDA Analysis Finds No New or Unexpected Safety Risks of Pimavanserin:Benefits Outweigh Risks

Thursday, September 20, 2018—The Food and Drug Administration (FDA) announced that there are no new safety concerns for pimavanserin (Nuplazid; Acadia Pharma, San Diego, CA). Pimavanserin is approved for …

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC